Here's Why You Should Add Inogen Stock to Your Portfolio Now

INGN gains momentum from rising POC demand, new product launches and strong Q3 sales, even as competition and forex swings temper near-term growth.

Zacks Investment Research • Dec 5, 2025

Down 19.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Inogen (INGN)

Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research • Nov 14, 2025

Slow Progress At Inogen

Inogen (INGN) continues its turnaround, showing progress in revenue growth and margins, but the pace remains slower and riskier than the market desires. INGN posted positive adjusted EBITDA and raised full-year guidance, despite mixed quarterly results and ongoing volatility in direct-to-consumer and rental segments. The company's strong market position, new product launches, and partnerships offer long-term growth potential, especially as patients consistently prefer portable solutions.

Seeking Alpha • Nov 11, 2025

Inogen Stock Dips Despite Q3 Earnings Beat, Revenues Up Y/Y

INGN stock slid despite a narrower Q3 loss and rising B2B demand, as weaker consumer and rental sales weighed on results.

Zacks Investment Research • Nov 6, 2025

Inogen, Inc. (INGN) Q3 2025 Earnings Call Transcript

Inogen, Inc. ( INGN ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Lorna Williams Kevin Smith - President, CEO & Director Michael Bourque - Executive VP, CFO & Corporate Treasurer Conference Call Participants Joseph Conway - Needham & Company, LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Presentation Operator Welcome to Inogen's Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Nov 5, 2025

Inogen Announces Third Quarter 2025 Financial Results

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Third Quarter 2025 Financial Results Delivered seventh consecutive quarter of mid-single-digit revenue growth.

Business Wire • Nov 5, 2025

Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates

Inogen (INGN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.25 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Inogen to Report Third Quarter 2025 Financial Results on November 5, 2025

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. On the same day, the Company will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961.

Business Wire • Oct 15, 2025

Why Fast-paced Mover Inogen (INGN) Is a Great Choice for Value Investors

Inogen (INGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research • Sep 30, 2025

Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer

GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer.

Business Wire • Sep 25, 2025